Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

VCYT

Veracyte Inc

Feb 06 • 04:00PM ET

36.19

+1.33 3.82 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: EXAS ILMN GH BIO NTRA MYGN CDNA QGEN FLGT CRL

| Held by: IJR VTI VB ARKK FBT IWM XBI VBK ARKG VXF

Index	RUT	P/E	95.31	EPS (ttm)	0.38	Insider Own	2.16%	Shs Outstand	79.03M	Perf Week	-4.96%
Market Cap	2.86B	Forward P/E	23.13	EPS next Y	1.56	Insider Trans	-10.01%	Shs Float	77.34M	Perf Month	-19.77%
Enterprise Value	2.53B	PEG	0.30	EPS next Q	0.41	Inst Own	110.68%	Short Float	6.69%	Perf Quarter	-21.39%
Income	30.32M	P/S	5.78	EPS this Y	436.38%	Inst Trans	0.43%	Short Ratio	6.03	Perf Half Y	30.74%
Sales	495.14M	P/B	2.27	EPS next Y	-5.90%	ROA	2.29%	Short Interest	5.18M	Perf YTD	-14.04%
Book/sh	15.91	P/C	7.81	EPS next 5Y	76.17%	ROE	2.49%	52W High	50.71 -28.63%	Perf Year	-19.93%
Cash/sh	4.64	P/FCF	29.13	EPS past 3/5Y	- -	ROIC	2.34%	52W Low	22.61 60.06%	Perf 3Y	39.41%
Dividend Est.	-	EV/EBITDA	35.30	Sales past 3/5Y	26.63% 29.93%	Gross Margin	66.85%	Volatility	5.79% 4.73%	Perf 5Y	-40.40%
Dividend TTM	-	EV/Sales	5.12	EPS Y/Y TTM	375.89%	Oper. Margin	9.98%	ATR (14)	1.82	Perf 10Y	458.49%
Dividend Ex-Date	-	Quick Ratio	5.94	Sales Y/Y TTM	16.41%	Profit Margin	6.12%	RSI (14)	33.99	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	6.23	EPS Q/Q	24.34%	SMA20	-9.90%	Beta	1.92	Target Price	49.18
Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	13.82%	SMA50	-15.03%	Rel Volume	1.40	Prev Close	34.86
Employees	824	LT Debt/Eq	0.03	Earnings	Feb 25 AMC	SMA200	6.80%	Avg Volume	858.30K	Price	36.19
IPO	Oct 30, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	59.13% 5.52%	Trades		Volume	1,203,271	Change	3.82%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Resumed	Morgan Stanley	Underweight	$48
Oct-20-25	Initiated	Canaccord Genuity	Hold	$40
Mar-20-25	Initiated	Craig Hallum	Buy	$45
Dec-05-24	Downgrade	Goldman	Buy → Neutral	$38 → $37
Nov-15-24	Initiated	Wolfe Research	Outperform	$50
Oct-16-24	Initiated	UBS	Buy	$43
Oct-10-24	Initiated	Guggenheim	Buy	$40
Feb-23-24	Reiterated	Needham	Buy	$30 → $33
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$33
Jan-07-22	Initiated	Stephens	Overweight	$52
Nov-18-21	Resumed	Goldman	Buy	$60
Jun-15-21	Initiated	Raymond James	Outperform	$45
Feb-18-21	Resumed	Needham	Buy	$88
Jan-28-21	Initiated	Truist	Buy	$61
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight	$48
Sep-09-20	Initiated	Morgan Stanley	Underweight	$35
Jul-31-19	Initiated	Lake Street	Buy	$35
Jul-02-19	Initiated	Needham	Buy	$33
Nov-29-18	Downgrade	Janney	Buy → Neutral

Show Previous Ratings

Feb-06-26 09:45AM	Here's How Quest Diagnostics Is Placed Ahead of Q4 Earnings (Zacks)
Feb-05-26 05:40PM	Mettler-Toledo (MTD) Q4 Earnings and Revenues Beat Estimates (Zacks)
12:56PM	Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes (Zacks)
12:33PM	DXCM Upgrades Stelo With AI-Powered Smart Meal Logging Features (Zacks)
09:35AM	Veracyte (VCYT) Loses 20.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
05:15PM	Loading…
Feb-04-26 05:15PM	Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 (Business Wire)
12:57PM	Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test (Zacks)
12:51PM	Here's Why You Should Add Masimo Stock to Your Portfolio Now (Zacks)
10:23AM	Edwards Lifesciences' Q4 Earnings on Deck: Here's What to Expect (Zacks)
09:45AM	Here's Why Veracyte (VCYT) is a Strong Growth Stock (Zacks)
08:47AM	Will Pharmacy and Consumer Wellness Segment Lead CVS' Q4 Earnings? (Zacks)
Feb-03-26 01:13PM	GEHC Wins FDA Clearance & CE Mark for Allia Moveo, Marks Global Debut (Zacks)
11:38AM	Zimmer Biomet to Report Q4 Earnings: Here's What to Expect (Zacks)
Feb-02-26 11:57AM	BD & Envetec Showcase Closed-Loop Recycling Solution for Lab Plastics (Zacks)
09:37AM	ILMN Q4 Earnings Preview: NovaSeq X Momentum Likely to Aid Performance (Zacks)
09:13AM	Loading…
09:13AM	Can Cannabis Strength in Canada Drive Canopy's Q3 Earnings? (Zacks)
Jan-30-26 01:34PM	GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test (Zacks)
09:55AM	Here's Why Veracyte (VCYT) Is a Great 'Buy the Bottom' Stock Now (Zacks)
08:28AM	HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash (Zacks)
Jan-29-26 01:32PM	Reasons to Retain Avanos Medical Stock in Your Portfolio Now (Zacks)
01:28PM	Organon Completes Divesture of JADA System to Laborie Medical (Zacks)
08:02AM	Here's How Align Technology Is Placed Ahead of Q4 Earnings (Zacks)
Jan-28-26 12:21PM	Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums (Zacks)
11:26AM	QT Imaging & Olea Medical Partner to Enhance Cloud Imaging Platform (Zacks)
09:11AM	Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings? (Zacks)
08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
07:46AM	PAHC Q2 Earnings Preview: Animal Health Momentum Likely to Aid Results (Zacks)
07:43AM	Here's How IDEXX Laboratories Is Placed Ahead of Q4 Earnings (Zacks)
07:27AM	Will Robust MedSurg Performance Fuel Boston Scientific's Q4 Earnings? (Zacks)
07:26AM	STERIS' Q3 Earnings on Deck: What's in Store for the Stock? (Zacks)
12:19PM	Loading…
Jan-27-26 12:19PM	Here's Why You Should Add Merit Medical Stock to Your Portfolio Now (Zacks)
12:07PM	ISRG's da Vinci Gets FDA Nod for Advanced Cardiac Procedures (Zacks)
07:54AM	Resmed's Q2 Earnings on Deck: What's in Store for the Stock? (Zacks)
07:53AM	CLPT Gets EU MDR Certification for ClearPoint Navigation Software (Zacks)
Jan-26-26 12:10PM	Why Veracyte (VCYT) is Poised to Beat Earnings Estimates Again (Zacks)
Jan-23-26 01:50PM	WST Launches Synchrony S1 Prefillable Syringe at Pharmapack (Zacks)
07:17AM	Can Specialty Diagnostics Strength Drive Thermo Fisher's Q4 Earnings? (Zacks)
Jan-22-26 11:08AM	Here's Why You Should Retain Integer Holdings Stock in Your Portfolio (Zacks)
09:50AM	Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term (Zacks)
03:25AM	Veracyte, Inc. (VCYT) Sees Analyst Support as Guggenheim Reaffirms Buy Rating (Insider Monkey)
Jan-21-26 01:29PM	Centene Expands Palliative Care Access in Ohio Through Tuesday Health (Zacks)
11:43AM	BD Gets FDA 510(k) Approval for EnCor EnCompass Breast Biopsy System (Zacks)
Jan-19-26 12:40PM	Elekta Wins FDA Nod for Evo CT-Linac, Boosting U.S. Radiation Oncology (Zacks)
07:37AM	Will Robust Adult Nutrition Business Performance Fuel ABT's Q4 Earnings? (Zacks)
Jan-14-26 01:11PM	Option Care Health Stock Earns Healthy RS Rating Upgrade (Investor's Business Daily)
Jan-13-26 10:45AM	NTRA & NVDA Partner to Improve AI Models for Precision Medicine (Zacks)
Jan-12-26 08:57AM	RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models (Zacks)
Jan-11-26 04:30PM	Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Business Wire)
Jan-08-26 09:00AM	The Zacks Rank Explained: How to Find Strong Buy Medical Stocks (Zacks)
Jan-07-26 12:24PM	BFLY to Extend 3D Imaging Capabilities to Butterfly Garden Developers (Zacks)
Jan-05-26 12:51PM	Here's Why You Should Retain Masimo Stock in Your Portfolio Now (Zacks)
Dec-31-25 07:25AM	Smart Oncology: 5 Stocks Chasing the $317B Prize (PR Newswire)
Dec-30-25 11:48PM	Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT) (Insider Monkey)
10:42AM	RBOT Enters Strategic Software Partnership to Streamline Development (Zacks)
05:48AM	Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical (Zacks)
Dec-29-25 04:30PM	Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
07:23AM	3 Medical Instrument Stocks to Counter Industry Woes Using GenAI (Zacks)
Dec-26-25 12:20PM	EW Wins FDA Approval for SAPIEN M3 as First Transseptal TMVR Therapy (Zacks)
Dec-23-25 02:08PM	Is This the Right Time to Add Veracyte Stock to Your Portfolio? (Zacks)
Dec-17-25 12:01PM	HOLX's Genius AI Mammography Flags Missed Breast Cancer Cases (Zacks)
Dec-11-25 10:06AM	ISRG Gets FDA Clearance to Use da Vinci SP Robot for General Surgeries (Zacks)
Dec-10-25 12:40PM	PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor (Zacks)
08:59AM	Here's Why You Should Add Cencora Stock to Your Portfolio Now (Zacks)
Dec-08-25 08:23AM	Beat the Market the Zacks Way: Veracyte, Las Vegas Sands, 3M in Focus (Zacks)
Dec-03-25 11:59AM	EHC Opens New Lake Worth Rehab Hospital to Meet Rising Demand (Zacks)
Dec-02-25 09:45AM	Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term (Zacks)
Nov-19-25 12:24PM	TDOC Partners With TytoCare to Expand At-Home Exam Capabilities (Zacks)
Nov-13-25 11:07AM	Ensign Group Shares Decline 2.2% Despite Q3 Earnings Beat (Zacks) -5.74%
Nov-11-25 12:24PM	Encompass Health Shares Down 8% Despite Q3 Earnings & Revenue Beat (Zacks)
07:26AM	VCYT Stock Gains on Q3 Earnings and Revenue Beat, '25 View Up (Zacks)
Nov-10-25 12:55PM	Tenet Healthcare Shares Down 5% Despite Q3 Earnings Beat (Zacks)
Nov-06-25 12:09PM	Pediatrix Medical Q3 Earnings Beat Estimates on Declining Expenses (Zacks) -9.45%
08:30AM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
Nov-05-25 12:03AM	Veracyte Inc (VCYT) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) +27.46%
Nov-04-25 06:25PM	Veracyte (VCYT) Q3 Earnings and Revenues Beat Estimates (Zacks)
05:31PM	Veracyte: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 04:15PM	Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing (Business Wire)
07:31AM	What To Expect From Veracyte Inc (VCYT) Q3 2025 Earnings (GuruFocus.com)
Oct-31-25 10:17AM	EW Stock Gains on Q3 Earnings and Revenue Beat, Margins Crash (Zacks)
Oct-30-25 12:24PM	ALGN Stock Up on Q3 Earnings and Revenue Beat, Margins Crash (Zacks)
Oct-29-25 09:08AM	CHE Stock Falls on Q3 Earnings and Revenue Miss, Margins Crash (Zacks)
Oct-28-25 10:01AM	LH Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down (Zacks)
Oct-24-25 01:53PM	ITGR Shares Down Despite Q3 Earnings & Revenues Beat Estimates (Zacks)
Oct-22-25 10:56AM	ISRG Stock Gains on Q3 Earnings & Revenue Beat, Gross Margin Declines (Zacks)
09:23AM	Boston Scientific Beats on Q3 Earnings, Raises 2025 View, Stock Up (Zacks)
09:16AM	Thermo Fisher's Q3 Earnings & Revenues Top Estimates, Stock Climbs (Zacks)
08:30AM	Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today (Zacks)
Oct-21-25 09:29AM	Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise (Zacks)
Oct-16-25 09:35AM	Veracyte (VCYT) Crossed Above the 20-Day Moving Average: What That Means for Investors (Zacks)
08:06AM	Do You Believe in the Upside Potential of Veracyte (VCYT) (Insider Monkey)
Oct-15-25 05:31PM	Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025 (Business Wire)
10:12AM	Abbott's Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Climbs (Zacks)
Oct-07-25 09:00AM	This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar (Zacks)
Oct-06-25 08:30AM	If You Invested $1000 in Veracyte a Decade Ago, This is How Much It'd Be Worth Now (Zacks)
Sep-29-25 09:50AM	Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term (Zacks)
Sep-28-25 04:00PM	Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer (Business Wire)
Sep-25-25 09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:15AM	Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus (PR Newswire)
Sep-24-25 09:00AM	Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025 (Business Wire)

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McGuire Annie	SVP, General Counsel	Dec 16 '25	Sale	43.13	10,739	463,204	67,760	Dec 17 04:35 PM
ANN MCGUIRE	Officer	Dec 16 '25	Proposed Sale	43.53	10,739	467,469		Dec 16 04:30 PM
EASTHAM KARIN	Director	Dec 05 '25	Option Exercise	7.77	20,000	155,400	33,554	Dec 08 04:34 PM
EASTHAM KARIN	Director	Dec 05 '25	Sale	45.45	20,000	908,923	13,554	Dec 08 04:34 PM
KARIN EASTHAM	Director	Dec 05 '25	Proposed Sale	47.41	20,000	948,200		Dec 05 04:26 PM
McGuire Annie	SVP, General Counsel	Dec 04 '25	Sale	47.30	1,422	67,261	78,499	Dec 04 07:44 PM
Chambers Rebecca	Chief Financial Officer	Dec 04 '25	Sale	46.84	13,278	621,955	109,496	Dec 04 07:44 PM
Stapley Marc	Chief Executive Officer	Dec 04 '25	Sale	47.09	7,668	361,076	318,603	Dec 04 07:44 PM
Leite John	Chief Commercial Officer-CLIA	Dec 04 '25	Sale	47.51	1,278	60,718	82,113	Dec 04 07:43 PM
ANN MCGUIRE	Officer	Dec 04 '25	Proposed Sale	47.75	1,422	67,900		Dec 04 04:39 PM
REBECCA CHAMBERS	Officer	Dec 04 '25	Proposed Sale	47.75	13,278	634,024		Dec 04 04:39 PM
MARC STAPLEY	Director	Dec 04 '25	Proposed Sale	47.75	7,668	366,147		Dec 04 04:38 PM
Leite John	Chief Commercial Officer-CLIA	Nov 25 '25	Sale	50.00	2,808	140,400	86,291	Nov 26 04:27 PM
JONES EVAN/ FA	Director	Nov 25 '25	Sale	50.25	1,106	55,576	29,362	Nov 26 04:27 PM
Evan Jones	Director	Nov 25 '25	Proposed Sale	49.38	5,000	246,900		Nov 25 07:25 PM
John Leite	Officer	Nov 25 '25	Proposed Sale	46.70	4,086	190,816		Nov 25 04:28 PM
Holstein Jens	Director	Nov 20 '25	Sale	42.36	10,000	423,563	27,199	Nov 21 04:19 PM
JENS HOLSTEIN	Director	Nov 20 '25	Proposed Sale	42.36	10,000	423,563		Nov 20 04:03 PM
Wygant Jonathan	VP, Chief Accounting Officer	Nov 07 '25	Sale	40.21	5,818	233,929	43,847	Nov 12 04:25 PM
Wygant Jonathan	VP, Chief Accounting Officer	Nov 10 '25	Sale	42.33	5,102	215,978	38,745	Nov 12 04:25 PM
McGuire Annie	SVP, General Counsel	Nov 05 '25	Sale	40.00	6,466	258,640	82,973	Nov 07 04:10 PM
JONES EVAN/ FA	Director	Nov 05 '25	Option Exercise	6.94	30,000	208,200	73,664	Nov 07 04:10 PM
JONES EVAN/ FA	Director	Nov 05 '25	Sale	45.06	43,196	1,946,288	30,468	Nov 07 04:10 PM
EASTHAM KARIN	Director	Nov 05 '25	Sale	40.02	9,674	387,191	13,554	Nov 07 04:10 PM
Chambers Rebecca	Chief Financial Officer	Nov 05 '25	Sale	41.00	7,000	287,000	126,158	Nov 07 04:10 PM
Evan Jones	Director	Nov 05 '25	Proposed Sale	46.04	43,196	1,988,744		Nov 05 09:47 PM
KARIN EASTHAM	Director	Nov 05 '25	Proposed Sale	36.12	9,674	349,425		Nov 05 04:18 PM
ANN MCGUIRE	Officer	Nov 05 '25	Proposed Sale	36.12	6,466	233,552		Nov 05 04:18 PM
REBECCA CHAMBERS	Officer	Nov 05 '25	Proposed Sale	36.12	7,000	252,840		Nov 05 04:17 PM
Febbo Phillip G.	Chief Scientific & Med Officer	Oct 06 '25	Sale	36.02	8,349	300,709	92,441	Oct 07 04:27 PM
PHILLIP FEBBO	Officer	Oct 06 '25	Proposed Sale	36.00	8,349	300,564		Oct 06 04:19 PM
Leite John	Chief Commercial Officer-CLIA	Oct 01 '25	Sale	35.00	2,539	88,865	89,099	Oct 03 04:16 PM
EPSTEIN ROBERT S	Director	Oct 01 '25	Option Exercise	7.94	10,000	79,400	83,919	Oct 03 04:16 PM
EPSTEIN ROBERT S	Director	Oct 01 '25	Sale	35.08	21,473	753,204	62,446	Oct 03 04:16 PM
McGuire Annie	SVP, General Counsel	Oct 01 '25	Sale	35.00	2,160	75,608	89,439	Oct 03 04:16 PM
ROBERT S EPSTEIN	Director	Oct 01 '25	Proposed Sale	34.33	21,473	737,168		Oct 01 04:27 PM
John Leite	Officer	Oct 01 '25	Proposed Sale	34.33	2,539	87,164		Oct 01 04:27 PM
ANN MCGUIRE	Officer	Oct 01 '25	Proposed Sale	34.33	2,160	74,153		Oct 01 04:26 PM
McGuire Annie	SVP, General Counsel	Sep 19 '25	Sale	33.69	2,283	76,920	91,599	Sep 23 04:18 PM
ANN MCGUIRE	Officer	Sep 19 '25	Proposed Sale	33.23	2,283	75,864		Sep 19 04:25 PM
Stapley Marc	Chief Executive Officer	Sep 04 '25	Sale	30.41	7,667	233,133	334,185	Sep 08 04:33 PM
MARC STAPLEY	Director	Sep 04 '25	Proposed Sale	30.62	7,667	234,764		Sep 04 04:26 PM
EASTHAM KARIN	Director	Jun 13 '25	Sale	26.66	4,590	122,388	13,907	Jun 17 04:21 PM
Bhanji Muna	Director	Jun 13 '25	Sale	26.67	4,589	122,367	29,989	Jun 17 04:21 PM
KARIN EASTHAM	Director	Jun 13 '25	Proposed Sale	26.69	4,590	122,507		Jun 13 04:46 PM
MUNA BHANJI	Director	Jun 13 '25	Proposed Sale	26.69	4,589	122,480		Jun 13 04:45 PM
Leite John	Chief Commercial Officer-CLIA	Jun 04 '25	Sale	27.20	2,809	76,410	94,540	Jun 06 04:19 PM
JOHN LEITE	Officer	Jun 04 '25	Proposed Sale	26.50	2,809	74,438		Jun 04 04:21 PM
Leite John	Chief Commercial Officer-CLIA	Mar 07 '25	Sale	31.66	7,411	234,630	100,249	Mar 10 04:43 PM
JOHN LEITE	Officer	Mar 07 '25	Proposed Sale	32.51	7,411	240,932		Mar 07 04:17 PM
ANN MCGUIRE	Officer	Mar 04 '25	Proposed Sale	33.56	1,142	38,326		Mar 04 05:12 PM
MARC STAPLEY	Director	Mar 04 '25	Proposed Sale	33.56	52,697	1,768,511		Mar 04 05:07 PM
PHILLIP FEBBO	Officer	Mar 04 '25	Proposed Sale	33.56	8,037	269,722		Mar 04 05:07 PM
Leite John	Chief Commercial Officer-CLIA	Feb 27 '25	Sale	33.84	5,746	194,445	79,070	Mar 03 04:30 PM

Open in Screener

GKOS

Glaukos Corporation

Feb 06 • 04:00PM ET

112.52

-1.00 -0.88 %

Healthcare • Medical Devices • USA • NYSE

GKOS Glaukos Corporation daily Stock Chart

Peers: ALGN ZBH BSX EW ISRG MDT SYK COO BAX HOLX

| Held by: IJR VTI IWM VB VBK VXF SPSM IWO IJT SCHA

Index	RUT	P/E	-	EPS (ttm)	-1.55	Insider Own	4.25%	Shs Outstand	57.39M	Perf Week	-5.75%
Market Cap	6.46B	Forward P/E	-	EPS next Y	-0.32	Insider Trans	-12.08%	Shs Float	55.00M	Perf Month	-1.06%
Enterprise Value	6.29B	PEG	-	EPS next Q	-0.20	Inst Own	100.55%	Short Float	4.05%	Perf Quarter	33.40%
Income	-87.61M	P/S	13.76	EPS this Y	56.14%	Inst Trans	-6.44%	Short Ratio	2.54	Perf Half Y	27.86%
Sales	469.82M	P/B	8.39	EPS next Y	60.85%	ROA	-9.10%	Short Interest	2.23M	Perf YTD	-0.35%
Book/sh	13.41	P/C	23.61	EPS next 5Y	-	ROE	-12.19%	52W High	161.78 -30.45%	Perf Year	-28.38%
Cash/sh	4.77	P/FCF	-	EPS past 3/5Y	-37.46% -	ROIC	-10.03%	52W Low	73.16 53.80%	Perf 3Y	126.13%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	9.26% 10.10%	Gross Margin	76.87%	Volatility	4.12% 5.11%	Perf 5Y	25.69%
Dividend TTM	-	EV/Sales	13.39	EPS Y/Y TTM	47.64%	Oper. Margin	-18.82%	ATR (14)	5.43	Perf 10Y	589.46%
Dividend Ex-Date	-	Quick Ratio	4.47	Sales Y/Y TTM	30.38%	Profit Margin	-18.65%	RSI (14)	45.01	Recom	1.38
Dividend Gr. 3/5Y	- -	Current Ratio	5.20	EPS Q/Q	27.30%	SMA20	-4.17%	Beta	0.71	Target Price	132.71
Payout	-	Debt/Eq	0.14	Sales Q/Q	38.14%	SMA50	-1.01%	Rel Volume	1.09	Prev Close	113.52
Employees	995	LT Debt/Eq	0.14	Earnings	Feb 17 AMC	SMA200	16.20%	Avg Volume	876.45K	Price	112.52
IPO	Jun 25, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	38.60% 9.06%	Trades		Volume	951,647	Change	-0.88%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-27-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$120
Oct-01-25	Initiated	Goldman	Buy	$103
May-01-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$86
Feb-19-25	Upgrade	Mizuho	Neutral → Outperform	$140 → $200
Dec-11-24	Upgrade	Citigroup	Neutral → Buy	$132 → $162
Dec-06-24	Initiated	UBS	Buy	$182
Dec-02-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$120
Jul-10-24	Downgrade	Citigroup	Buy → Neutral	$132
May-06-24	Upgrade	Jefferies	Hold → Buy	$84 → $125
Dec-21-23	Upgrade	JP Morgan	Neutral → Overweight	$66 → $91
Dec-04-23	Initiated	Morgan Stanley	Equal-Weight	$65
Nov-28-23	Initiated	Truist	Buy	$88
Nov-08-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$75 → $83
Jun-07-23	Upgrade	Piper Sandler	Neutral → Overweight	$55 → $80
Dec-22-22	Initiated	Mizuho	Neutral	$48
Dec-19-22	Upgrade	JP Morgan	Underweight → Neutral	$48 → $42
Dec-12-22	Upgrade	Citigroup	Neutral → Buy	$57
Oct-14-22	Resumed	Stephens	Overweight	$69
Oct-04-22	Initiated	Needham	Buy	$66
Jul-12-22	Upgrade	Stifel	Hold → Buy	$40 → $60

Show Previous Ratings

Jan-29-26 09:55AM	Wells sees potential upside after Glaukos iDose repeat dosing label approved (TipRanks)
08:32AM	Here's Why You Should Retain Glaukos Stock in Your Portfolio Now (Zacks)
Jan-28-26 07:00AM	Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose TR (Business Wire)
Jan-22-26 04:30AM	What Makes Glaukos (GKOS) a Good Investment? (Insider Monkey)
Jan-20-26 07:00AM	Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17 (Business Wire)
04:39PM	Loading…
Jan-14-26 04:39PM	Stock Indexes Settle Lower on Tech Weakness (Barchart) -5.26% +9.62%
04:19PM	Intuitive Surgical Crushed Fourth-Quarter Forecasts. So Why Did Shares Dive? (Investor's Business Daily)
Jan-13-26 04:05PM	Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance (Business Wire)
Jan-03-26 07:20AM	Klaviyo, Wingstop among Stephens Best Ideas for 2026 (TipRanks)
07:10AM	Glaukos price target raised to $145 from $115 at Stephens (TipRanks)
Dec-29-25 08:52AM	Here's Why You Should Retain Glaukos Stock in Your Portfolio Now (Zacks)
Dec-16-25 07:00AM	Glaukos Announces Participation in J.P. Morgan Healthcare Conference (Business Wire)
Dec-05-25 11:30AM	Inogen (INGN) Down 0.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-03-25 11:30AM	Idexx (IDXX) Up 1.5% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-28-25 12:44PM	Here's Why You Should Retain Glaukos Stock in Your Portfolio (Zacks)
11:30AM	Loading…
11:30AM	Glaukos (GKOS) Up 20% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-05-25 06:08AM	Beaten Down by 35%-Plus: Analysts Say These 2 Oversold Stocks Are Poised to Turn the Corner (TipRanks)
Nov-03-25 07:00AM	Glaukos Announces Participation in Upcoming Investor Conferences (Business Wire)
Oct-31-25 06:03PM	Here's What Key Metrics Tell Us About Glaukos (GKOS) Q3 Earnings (Zacks)
Oct-30-25 06:54PM	Why Glaukos Stock Zoomed Almost 14% Higher on Thursday (Motley Fool) +13.89%
04:06PM	Glaukos Corp (GKOS) Q3 2025 Earnings Call Highlights: Record Sales and Strategic Advancements (GuruFocus.com)
12:21PM	GKOS Stock Surges Following Q3 Earnings & Revenue Beat, Guidance Raised (Zacks)
Oct-29-25 05:55PM	Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:51PM	Glaukos: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Third Quarter 2025 Financial Results (Business Wire)
Oct-28-25 09:33AM	What To Expect From Glaukos Corp (GKOS) Q3 2025 Earnings (GuruFocus.com)
08:15AM	IQVIA Holdings (IQV) Tops Q3 Earnings and Revenue Estimates (Zacks)
Oct-27-25 09:44AM	Microsoft upgraded, Harley-Davidson downgraded: Wall Street's top analyst calls (The Fly)
Oct-23-25 10:00AM	DexCom (DXCM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-22-25 10:00AM	Will Glaukos (GKOS) Report Negative Earnings Next Week? What You Should Know (Zacks)
07:00AM	Loading…
Oct-20-25 07:00AM	Glaukos Announces FDA Approval of Epioxa (Business Wire) -8.83%
06:31AM	Glaukos Corporation (GKOS) Eye Treatment Epioxa Poised for Strong Market Uptake, Says Stifel (Insider Monkey)
Oct-14-25 07:00AM	Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting (Business Wire)
Oct-08-25 07:00AM	Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29 (Business Wire)
Oct-01-25 11:01AM	Goldman Sachs initiates ophthalmology coverage: Buy Glaukos, sell Cooper (Investing.com)
Sep-25-25 04:05PM	Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama (Business Wire)
Sep-18-25 10:40AM	Glaukos Corporation (GKOS) Advances Next-Gen Glaucoma and Corneal Therapies, Eyes FDA Approval for Epioxa (Insider Monkey)
Sep-02-25 10:10AM	Glaukos Builds Dual Growth Engines Amid Market Headwinds (Zacks)
Aug-13-25 07:00AM	Glaukos Announces Participation in Wells Fargo Healthcare Conference (Business Wire)
Jul-31-25 01:27PM	GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised (Zacks) -8.46%
Jul-30-25 05:45PM	Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:43PM	Glaukos: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Second Quarter 2025 Financial Results (Business Wire)
Jul-29-25 09:30AM	Glaukos Corp (GKOS) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Jul-09-25 08:18AM	Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks (Zacks)
07:00AM	Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30 (Business Wire)
Jul-08-25 08:00AM	FELIQS Appoints Gregory Kunst and Joe Zenkus to Board of Directors (Business Wire)
Jun-27-25 10:37AM	Glaukos gains EU certification for iStent infinite and other MIGS devices (Medical Device Network)
Jun-25-25 04:05PM	Glaukos Announces EU MDR Certification for iStent infinite and Other Leading MIGS Therapies (Business Wire)
08:55AM	NYSE Content Advisory: Pre-Market update + S&P 500 trades within 1% of record (PR Newswire)
07:00AM	Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell (Business Wire)
Jun-16-25 12:00PM	What Makes Glaukos (GKOS) a New Buy Stock (Zacks)
Jun-11-25 09:55AM	Can Glaukos (GKOS) Climb 34.4% to Reach the Level Wall Street Analysts Expect? (Zacks)
May-21-25 07:17AM	Here's Why You Should Retain Glaukos Stock in Your Portfolio (Zacks)
May-13-25 07:00AM	Glaukos Announces Participation in Upcoming Investor Conferences (Business Wire)
May-12-25 08:13AM	Glaukos Corporation (GKOS) Fell as its iDose Results Fell Short of Expectations (Insider Monkey) +5.20%
May-07-25 04:55AM	Fidelity Select Health Care Portfolio Q1 2025 Commentary (Seeking Alpha)
May-01-25 12:00PM	Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -11.36%
11:32AM	GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline (Zacks)
11:04AM	Q1 2025 Glaukos Corp Earnings Call (Thomson Reuters StreetEvents)
03:17AM	Glaukos Corp (GKOS) Q1 2025 Earnings Call Highlights: Record Sales and Strategic Growth Amid ... (GuruFocus.com)
Apr-30-25 10:05PM	Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:22PM	Glaukos: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces First Quarter 2025 Financial Results (Business Wire)
Apr-29-25 01:10PM	ECL Stock Up in Pre-Market Following Q1 Earnings Meet Estimates (Zacks)
11:30AM	Baron Health Care Fund Q1 2025 Top Contributors And Detractors (Seeking Alpha)
Apr-28-25 01:18PM	RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up (Zacks)
11:24AM	Avantor Stock Declines Despite Q1 Earnings In-Line, Revenues Down Y/Y (Zacks)
Apr-27-25 02:22PM	Baron Health Care Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-25-25 12:50PM	Here's Why You Should Hold the GEHC Stock in Your Portfolio for Now (Zacks)
12:48PM	Integer Holdings Q1 Earnings & Revenues Beat Estimates, Margins Expand (Zacks)
Apr-24-25 01:02PM	Here's Why You Should Add Veeva Stock to Your Portfolio Now (Zacks)
11:36AM	WST Stock Rises on Q1 Earnings Beat, EPS View Up on Tariff & FX Benefit (Zacks)
10:01AM	Earnings Preview: Mettler-Toledo (MTD) Q1 Earnings Expected to Decline (Zacks)
Apr-23-25 12:39PM	ISRG Stock Falls Despite Q1 Earnings Beat, Gross Margin Contracts (Zacks)
10:01AM	Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
07:00AM	Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (Business Wire)
Apr-16-25 07:00AM	Glaukos Announces the Release of its 2024 Sustainability Report (Business Wire) -6.05%
Apr-10-25 09:04AM	Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength? (Zacks)
Apr-09-25 07:00AM	Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30 (Business Wire) +13.71%
Apr-08-25 09:41AM	What Makes Glaukos Corporation (GKOS) a Compelling Stock? (Insider Monkey)
Apr-07-25 08:00AM	ClearBridge Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-06-25 08:48AM	Glaukos: Macro Environment And Limited Market Access Could Stunt Growth Plans (Seeking Alpha)
Apr-02-25 12:01AM	Lord Abbett Developing Growth Fund Q4 2024 Commentary (Seeking Alpha)
Apr-01-25 10:49AM	The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals (Zacks)
Mar-31-25 09:10AM	3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space (Zacks)
Mar-28-25 03:59PM	Baird Q4 2024 Small/Mid Cap Growth Equity Commentary (Seeking Alpha)
Mar-27-25 11:15AM	Columbia Select Mid Cap Growth Fund Q4 2024 Commentary (SeekingAlpha)
Mar-26-25 11:10AM	Columbia Acorn Fund Q4 2024 Commentary (SeekingAlpha)
Mar-11-25 07:00AM	RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire: A Next-Generation Visual Field Solution (Business Wire)
Mar-04-25 11:52PM	Is Glaukos Corporation (GKOS) the Best Medical Technology Stock to Buy According to Analysts? (Insider Monkey)
Feb-24-25 07:00AM	Glaukos Announces FDA Acceptance of NDA Submission for Epioxa (Business Wire)
Feb-21-25 07:47PM	Wingstop Stocks Dip Is an Opportunity, Analyst Says. Plus, Devon Energy, Cadence Design, and More. (Barrons.com) -20.01%
02:15AM	Glaukos Corp (GKOS) Q4 2024 Earnings Call Highlights: Record Sales and Strategic Growth Amid ... (GuruFocus.com)
Feb-20-25 05:40PM	Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:34PM	Glaukos: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
12:00PM	Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz (TipRanks)
08:54AM	What To Expect From Glaukos Corp (GKOS) Q4 2024 Earnings (GuruFocus.com)

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stapley Marc	Director	Jan 22 '26	Option Exercise	24.69	15,000	370,350	52,449	Jan 26 09:21 PM
Stapley Marc	Director	Jan 22 '26	Sale	127.71	15,000	1,915,576	37,449	Jan 26 09:21 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 22 '26	Option Exercise	55.18	10,498	579,280	102,864	Jan 26 09:05 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 22 '26	Sale	127.68	10,498	1,340,380	92,366	Jan 26 09:05 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 21 '26	Option Exercise	55.18	4,502	248,420	96,868	Jan 23 08:42 PM
Gilliam Joseph E	PRESIDENT & COO	Jan 21 '26	Sale	124.65	4,502	561,174	92,366	Jan 23 08:42 PM
Gilliam Joseph E	Officer	Jan 22 '26	Proposed Sale	127.68	10,498	1,340,378		Jan 22 04:27 PM
Stapley Marc	Director	Jan 22 '26	Proposed Sale	127.70	15,000	1,915,560		Jan 22 04:21 PM
Gilliam Joseph E	Officer	Jan 21 '26	Proposed Sale	124.65	4,502	561,168		Jan 21 04:40 PM
Burns Thomas William	CHAIRMAN & CEO	Jan 16 '26	Option Exercise	16.49	186,945	3,082,723	340,720	Jan 20 06:37 PM
Burns Thomas William	CHAIRMAN & CEO	Jan 08 '26	Option Exercise	16.49	88,055	1,452,027	241,830	Jan 20 06:37 PM
Burns Thomas William	CHAIRMAN & CEO	Jan 16 '26	Sale	115.00	186,945	21,498,675	153,775	Jan 20 06:37 PM
Burns Thomas William	CHAIRMAN & CEO	Jan 08 '26	Sale	115.00	88,055	10,126,325	153,775	Jan 20 06:37 PM
Burns Thomas William	Officer	Jan 16 '26	Proposed Sale	115.00	186,945	21,498,675		Jan 16 10:29 AM
Burns Thomas William	Officer	Jan 08 '26	Proposed Sale	115.00	88,055	10,126,325		Jan 08 04:09 PM
Kliman Gilbert H	Director	Dec 09 '25	Option Exercise	24.69	5,000	123,450	39,905	Dec 11 04:20 PM
Kliman Gilbert H	Director	Dec 09 '25	Sale	107.27	5,000	536,350	34,905	Dec 11 04:20 PM
Kliman Gilbert H	Director	Dec 09 '25	Proposed Sale	107.27	5,000	536,368		Dec 09 03:43 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Nov 25 '25	Sale	105.00	315	33,075	50,488	Nov 26 05:00 PM
Thurman Alex R.	Officer	Nov 25 '25	Proposed Sale	105.00	315	33,075		Nov 25 02:19 PM
Gilliam Joseph E	PRESIDENT & COO	Nov 18 '25	Sale	90.00	19,340	1,740,600	92,366	Nov 20 07:56 PM
Gilliam Joseph E	Officer	Nov 18 '25	Proposed Sale	90.00	19,340	1,740,600		Nov 18 12:41 PM
Navratil Tomas	CHIEF DEVELOPMENT OFFICER	Sep 22 '25	Sale	84.22	517	43,541	76,390	Sep 24 06:53 PM
Navratil Tomas	Officer	Sep 22 '25	Proposed Sale	84.22	517	43,541		Sep 22 04:36 PM
Navratil Tomas	CHIEF DEVELOPMENT OFFICER	Sep 11 '25	Sale	88.22	5,142	453,620	75,469	Sep 12 08:42 PM
Navratil Tomas	Officer	Sep 11 '25	Proposed Sale	88.22	5,142	453,608		Sep 11 04:38 PM
Hoffmeister David F	Director	Jun 11 '25	Option Exercise	32.00	25,000	800,000	31,918	Jun 13 07:43 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Mar 25 '25	Sale	106.84	1,520	162,399	53,431	Mar 27 07:14 PM
Thurman Alex R.	Officer	Mar 25 '25	Proposed Sale	106.84	1,520	162,402		Mar 25 04:23 PM
Foley Mark J	Director	Feb 26 '25	Option Exercise	29.26	40,000	1,170,350	74,936	Feb 28 05:57 PM
Foley Mark J	Director	Feb 26 '25	Sale	120.72	20,687	2,497,335	54,249	Feb 28 05:57 PM
Foley Mark J	Director	Feb 26 '25	Proposed Sale	120.72	20,687	2,497,263		Feb 26 03:57 PM
Navratil Tomas	CHIEF DEVELOPMENT OFFICER	Feb 14 '25	Sale	147.14	3,416	502,630	72,437	Feb 19 06:00 PM
Navratil Tomas	Officer	Feb 14 '25	Proposed Sale	147.14	3,416	502,630		Feb 14 10:13 AM

VCYT

Veracyte Inc

GKOS

Glaukos Corporation

Upgrade your FINVIZ experience